| Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial S Delany-Moretlwe, JP Hughes, P Bock, SG Ouma, P Hunidzarira, ... The Lancet 399 (10337), 1779-1789, 2022 | 240 | 2022 |
| Adverse drug reactions during drug-resistant TB treatment in high HIV prevalence settings: a systematic review and meta-analysis K Schnippel, C Firnhaber, R Berhanu, L Page-Shipp, E Sinanovic Journal of Antimicrobial Chemotherapy 72 (7), 1871-1879, 2017 | 65 | 2017 |
| Intensive adherence counselling for HIV‐infected individuals failing second‐line antiretroviral therapy in Johannesburg, South Africa MP Fox, R Berhanu, K Steegen, C Firnhaber, P Ive, D Spencer, ... Tropical Medicine & International Health 21 (9), 1131-1137, 2016 | 64 | 2016 |
| Performance of Xpert MTB/RIF, Xpert Ultra, and Abbott RealTime MTB for Diagnosis of Pulmonary Tuberculosis in a High-HIV-Burden Setting RH Berhanu, A David, P da Silva, K Shearer, I Sanne, W Stevens, L Scott Journal of clinical microbiology 56 (12), 10.1128/jcm. 00560-18, 2018 | 53 | 2018 |
| Consensus statement: management of drug-induced liver injury in HIV-positive patients treated for TB: guideline E Jong, F Conradie, A Black, C Menezes, MA John, G Meintjes Southern African Journal of HIV Medicine 14 (3), 113-119, 2013 | 51 | 2013 |
| Predictors of mortality and treatment success during treatment for rifampicin-resistant tuberculosis within the South African National TB Programme, 2009 to 2011: a cohort … K Schnippel, K Shearer, D Evans, R Berhanu, N Ndjeka International Journal of Infectious Diseases 39, 89-94, 2015 | 50 | 2015 |
| Marginal structural models to assess delays in second-line HIV treatment initiation in South Africa JK Rohr, P Ive, CR Horsburgh, R Berhanu, K Shearer, M Maskew, L Long, ... PloS one 11 (8), e0161469, 2016 | 46 | 2016 |
| Impact of Xpert MTB/RIF and decentralized care on linkage to care and drug-resistant tuberculosis treatment outcomes in Johannesburg, South Africa D Evans, T Sineke, K Schnippel, R Berhanu, C Govathson, A Black, ... BMC health services research 18, 1-12, 2018 | 41 | 2018 |
| Severe adverse events during second-line tuberculosis treatment in the context of high HIV Co-infection in South Africa: a retrospective cohort study K Schnippel, RH Berhanu, A Black, C Firnhaber, N Maitisa, D Evans, ... BMC Infectious Diseases 16, 1-10, 2016 | 40 | 2016 |
| Treatment outcomes among children, adolescents, and adults on treatment for tuberculosis in two metropolitan municipalities in Gauteng Province, South Africa KM Berry, CA Rodriguez, RH Berhanu, N Ismail, L Mvusi, L Long, ... BMC Public Health 19, 1-17, 2019 | 34 | 2019 |
| The impact of adverse events on health-related quality of life among patients receiving treatment for drug-resistant tuberculosis in Johannesburg, South Africa T Sineke, D Evans, K Schnippel, H van Aswegen, R Berhanu, N Musakwa, ... Health and quality of life outcomes 17, 1-15, 2019 | 34 | 2019 |
| Incidence and predictors of herpes zoster among antiretroviral therapy-naive patients initiating HIV treatment in Johannesburg, South Africa K Shearer, M Maskew, T Ajayi, R Berhanu, P Majuba, I Sanne, MP Fox International Journal of Infectious Diseases 23, 56-62, 2014 | 29 | 2014 |
| Persistently high early mortality despite rapid diagnostics for drug-resistant tuberculosis cases in South Africa K Schnippel, C Firnhaber, N Ndjeka, F Conradie, L Page-Shipp, ... The International Journal of Tuberculosis and Lung Disease 21 (10), 1106-1111, 2017 | 27 | 2017 |
| Developing a predictive risk model for first‐line antiretroviral therapy failure in South Africa JK Rohr, P Ive, CR Horsburgh, R Berhanu, K Shearer, M Maskew, L Long, ... Journal of the International AIDS Society 19 (1), 20987, 2016 | 25 | 2016 |
| Early outcomes of decentralized care for rifampicin-resistant tuberculosis in Johannesburg, South Africa: an observational cohort study R Berhanu, K Schnippel, E Mohr, K Hirasen, D Evans, S Rosen, I Sanne PloS one 11 (11), e0164974, 2016 | 24 | 2016 |
| Predictors of switch to and early outcomes on third-line antiretroviral therapy at a large public-sector clinic in Johannesburg, South Africa D Evans, K Hirasen, R Berhanu, G Malete, P Ive, D Spencer, ... AIDS Research and Therapy 15, 1-12, 2018 | 23 | 2018 |
| Does disseminated nontuberculous mycobacterial disease cause false-positive determine TB-LAM lateral flow assay results? A retrospective review JS Nel, CK Lippincott, R Berhanu, DC Spencer, IM Sanne, P Ive Clinical Infectious Diseases 65 (7), 1226-1228, 2017 | 23 | 2017 |
| Treatment outcomes of over 1000 patients on second‐line, protease inhibitor‐based antiretroviral therapy from four public‐sector HIV treatment facilities across Johannesburg … K Shearer, D Evans, F Moyo, JK Rohr, R Berhanu, L Van Den Berg, ... Tropical Medicine & International Health 22 (2), 221-231, 2017 | 23 | 2017 |
| Treatment and pregnancy outcomes of pregnant women exposed to second-line anti-tuberculosis drugs in South Africa I Mokhele, N Jinga, R Berhanu, T Dlamini, L Long, D Evans BMC pregnancy and childbirth 21, 1-11, 2021 | 22 | 2021 |
| The relation between efavirenz versus nevirapine and virologic failure in Johannesburg, South Africa K Shearer, AT Brennan, M Maskew, L Long, R Berhanu, I Sanne, MP Fox Journal of the International AIDS Society 17 (1), 19065, 2014 | 22 | 2014 |
Denise H EvansHealth Economics and Epidemiology Research Office, Department of Internal Medicine, School ofVerified email at heroza.org
